PMID- 23244352
OWN - NLM
STAT- MEDLINE
DCOM- 20130314
LR  - 20220409
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 12
DP  - 2012 Dec 17
TI  - Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.
PG  - 1082
LID - 10.1186/1471-2458-12-1082 [doi]
AB  - BACKGROUND: Besides being a causative agent for genital warts and cervical 
      cancer, human papillomavirus (HPV) contributes to 40-85% of cases of anal, 
      penile, vaginal and vulvar cancer and precancerous lesions. HPV types 16 & 18 in 
      particular contribute to 74-93% of these cases. Overall the number of new cases 
      of these four cancers may be relatively high implying notable health care cost to 
      society. The aim of this study was to estimate the incidence and the health care 
      sector costs of anal, penile, vaginal and vulvar cancer. METHODS: New anogenital 
      cancer patients were identified from the Danish National Cancer Register using 
      ICD-10 diagnosis codes. Resource use in the health care sector was estimated for 
      the year prior to diagnosis, and for the first, second and third years after 
      diagnosis. Hospital resource use was defined in terms of registered hospital 
      contacts, using DRG (Diagnosis Related Groups) and DAGS (Danish Outpatient Groups 
      System) charges as cost estimates for inpatient and outpatient contacts, 
      respectively. Health care consumption by cancer patients diagnosed in 2004-2007 
      was compared with that by an age- and sex-matched cohort without cancer. Hospital 
      costs attributable to four anogenital cancers were estimated using regression 
      analysis. RESULTS: The annual incidence of anal cancer in Denmark is 1.9 per 
      100,000 persons. The corresponding incidence rates for penile, vaginal and vulvar 
      cancer are 1.7, 0.9 and 3.6 per 100,000 males/females, respectively. The total 
      number of new cases of these four cancers in Denmark is about 270 per year. In 
      comparison, the total number of new cases cervical cancer is around 390 per year. 
      The total cost of anogenital cancer to the hospital sector was estimated to be 
      7.6 million Euros per year. Costs associated with anal and vulvar cancer 
      constituted the majority of the costs. CONCLUSIONS: Anogenital cancer incurs 
      considerable costs to the Danish hospital sector. It is expected that the current 
      HPV vaccination program will markedly reduce this burden.
FAU - Olsen, Jens
AU  - Olsen J
AD  - Centre for Applied Health Services Research and Technology Assessment (CAST), 
      University of Southern Denmark, J, B, Winslows Vej 9B, 5000, Odense C, Denmark. 
      jeo@cast.sdu.dk
FAU - Jorgensen, Tine Rikke
AU  - Jorgensen TR
FAU - Kofoed, Kristian
AU  - Kofoed K
FAU - Larsen, Helle Kiellberg
AU  - Larsen HK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121217
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Anus Neoplasms/economics/epidemiology
MH  - Cross-Sectional Studies
MH  - Denmark/epidemiology
MH  - Female
MH  - Hospital Costs/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - *Penile Neoplasms/economics/epidemiology
MH  - Registries
MH  - *Vaginal Neoplasms/economics/epidemiology
MH  - *Vulvar Neoplasms/economics/epidemiology
MH  - Young Adult
PMC - PMC3546065
EDAT- 2012/12/19 06:00
MHDA- 2013/03/15 06:00
PMCR- 2012/12/17
CRDT- 2012/12/19 06:00
PHST- 2012/05/22 00:00 [received]
PHST- 2012/12/13 00:00 [accepted]
PHST- 2012/12/19 06:00 [entrez]
PHST- 2012/12/19 06:00 [pubmed]
PHST- 2013/03/15 06:00 [medline]
PHST- 2012/12/17 00:00 [pmc-release]
AID - 1471-2458-12-1082 [pii]
AID - 10.1186/1471-2458-12-1082 [doi]
PST - epublish
SO  - BMC Public Health. 2012 Dec 17;12:1082. doi: 10.1186/1471-2458-12-1082.